Education, Science, Technology, Innovation and Life
Open Access
Sign In

A Clinical Evaluation of the HPV Antigen Rapid Test for Early Detection of Cervical Cancer

Download as PDF

DOI: 10.23977/medsc.2024.050408 | Downloads: 17 | Views: 214

Author(s)

Zhang Lei 1, Yang Feng 2, Zhu Junzhe 3

Affiliation(s)

1 Zhejiang Gongshang University, Hangzhou, Zhejiang, 310018, China
2 Community Health Service Center, Yipeng Street, Qiantang District, Hangzhou, Zhejiang, 310000, China
3 Wenzhou Medical University, Wenzhou, Zhejiang, 310000, China

Corresponding Author

Zhang Lei

ABSTRACT

Cervical cancer remains a pressing global health concern. The primary cause of this malignancy is infection with high-risk human papillomavirus (HPV) strains, primarily HPV-16 and HPV-18, which account for approximately 70% of all cases. The development of effective prevention and treatment strategies depends on the availability of reliable HPV detection methods. In this study, we evaluated the diagnostic performance of the HPV antigen rapid test using a cohort of 140 clinical specimens, comparing it against PCR assays. The rapid test demonstrated high accuracy, with a sensitivity of 95%, specificity of 99.2% and overall accuracy of 98.6%. These findings highlight the potential of the HPV antigen rapid test to enhance HPV screening and facilitate early diagnosis, thereby contributing to more effective global management and prevention of cervical cancer. In summary, the HPV Antigen Rapid Test Cassette emerges as a valuable tool for HPV screening and cervical cancer prevention. Its high sensitivity and specificity, combined with the ability to provide rapid results, make it particularly beneficial for point-of-care testing in resource-limited environments.

KEYWORDS

HPV, Cervical Cancer, Rapid Test, Diagnostics

CITE THIS PAPER

Zhang Lei, Yang Feng, Zhu Junzhe, A Clinical Evaluation of the HPV Antigen Rapid Test for Early Detection of Cervical Cancer. MEDS Clinical Medicine (2024) Vol. 5: 67-72. DOI: http://dx.doi.org/10.23977/medsc.2024.050408.

REFERENCES

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 68 (6):394–424.
[2] Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 2021; 9(2):e161-e169. 
[3] Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G (October 2013). "A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types". Virology 445 (1–2): 224–231.
[4] Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L. A review of human carcinogens—part B: biological agents. Lancet Oncol 2009;10(4):321–322.
[5] Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp. Ther. Med. 2020; 20: 186.
[6] Chen L, Watanabe K, Haruyama T, Kobayashi N. Simple and rapid human papillomavirus genotyping method by restriction fragment length polymorphism analysis with two restriction enzymes, J. Med. Virol. 85 (2013) 1229–1234.
[7] Kundrod KA, Jeronimo J, Vetter B, Maza M, Murenzi G, Phoolcharoen N, et al. Toward 70% cervical cancer screening coverage: Technical challenges and opportunities to increase access to human papillomavirus (HPV) testing. PLOS Glob Public Health 2023;3:e0001982.
[8] Lugo-Trampe A, Trujillo-Murillo KdC, Rodriguez-Sanchez IP, Barboza-Cerda MdC, Lugo-Trampe JdJ, Hernandez-Ramirez LC, Canseco-Avila LM, Espinoza-Ruiz M, Dominguez-Arrevillaga S, Delgado-Enciso I. A PCR-RFLP method for typing human papillomavirus type 16 variants. J Virol Methods 2013; 187(2):338–344.
[9] Ji T, Xu X, Wang X, Cao N, Han X, Wang M, Chen B, Lin Z, Jia H, Deng M, Xia Y, Guo X, Lei M, Liu Z, Zhou Q, Chen G. Background-free chromatographic detection of sepsis biomarker in clinical human serum through near-infrared to near-infrared upconversion immunolabeling. ACS Nano 2020; 14(12):16864–16874.
[10] Katki HA, Kinney, WK, Fetterman B, Lorey, T., Poitras, N.E., Cheung, L, Castle, P.E. (2011). Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice. Lancet Oncology 2011; 12, 663–672.
[11] Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd edition. Geneva: World Health Organization; 2014. Preface. Available from: https://www.ncbi.nlm.nih.gov/books/NBK269613/
[12] WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
[13] Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Damme P. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis. 2012; 31(5): 627-640.

Downloads: 6489
Visits: 310496

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.